Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan

Authors Horita N, Kaneko T

Received 4 December 2014

Accepted for publication 10 January 2015

Published 21 April 2015 Volume 2015:10(1) Pages 813—822

DOI https://doi.org/10.2147/COPD.S56067

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell

Nobuyuki Horita, Takeshi Kaneko

Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Abstract: Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. As of November 2014, more than 40 countries had approved this medication except for the USA. This is the first dual bronchodilator in one device. Now, the Breezhaler is the only device that can provide long-acting muscarinic antagonist (glycopyrronium bromide), long-acting beta agonist (indacaterol), and a combination of the two medications (QVA149). The choice among the three medications allows a patient to use the same inhalation device even when the regimen is changed from single-bronchodilator therapy to dual-bronchodilator therapy. In addition, the quick bronchodilation effect and once-daily administration can improve patient adherence to medical treatment for chronic obstructive pulmonary disease (COPD). To our knowledge, as of November 2014, the safety and the efficacy of QVA149 have been evaluated in 14 randomized controlled trials. The 14 trials generally showed good safety profiles, and there were better or not-inferior bronchodilator effects of QVA149 when compared with placebo, or other inhaled medication. According to the Japanese Respiratory Society guidelines, QVA149 is a combination of the two first-line bronchodilators. Our meta-analysis indicated that QVA149 is superior to the salmeterol–fluticasone combination to treat COPD in respect of the frequency of adverse effects, exacerbation, pneumonia, and improvement of trough forced expiratory volume in 1 second (FEV1). Thus, we believe that QVA149 can be a key medication for COPD treatments.

Keywords: bronchodilator agents, dry powder inhalers, delivery of health care, guideline, meta-analysis, muscarinic antagonists
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease

Andelid K, Andersson A, Yoshihara S, Åhrén C, Jirholt P, Ekberg-Jansson A, Lindén A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1253-1263

Published Date: 30 June 2015

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1015-1026

Published Date: 5 June 2015

Patient preferences in severe COPD and asthma: a comprehensive literature review

Bereza BG, Troelsgaard Nielsen A, Valgardsson S, Hemels MEH, Einarson TR

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:739-744

Published Date: 8 April 2015

The clinical use of regenerative therapy in COPD

Lipsi R, Rogliani P, Calzetta L, Segreti A, Cazzola M

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1389-1396

Published Date: 12 December 2014

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M

Patient Preference and Adherence 2014, 8:1713-1720

Published Date: 12 December 2014

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010